{"id":107140,"date":"2022-03-09T09:58:15","date_gmt":"2022-03-09T17:58:15","guid":{"rendered":"https:\/\/theavtimes.com\/?p=107140"},"modified":"2022-03-09T15:33:48","modified_gmt":"2022-03-09T23:33:48","slug":"scientists-from-cedars-sinai-discover-new-therapy-for-covid-19","status":"publish","type":"post","link":"https:\/\/theavtimes.com\/2022\/03\/09\/scientists-from-cedars-sinai-discover-new-therapy-for-covid-19\/","title":{"rendered":"Scientists from Cedars-Sinai discover new therapy for COVID-19"},"content":{"rendered":"

\"\"<\/a><\/p>\n

Scientists from Cedars-Sinai report research findings have opened the possibility to a new therapy for COVID-19 patients, a discovery made in a biologic substance created by reengineered human skin cells.<\/p>\n

The substance stopped SARS-CoV-2, the virus that causes COVID-19, from reproducing and protected cells when tested in human lung cells, scientists reported. The research is in early stages.<\/p>\n

The details of the therapy and findings were published in the journal “Biomaterials and Biosystems<\/a>.”<\/em><\/p>\n

“We were surprised to find this potential therapy shuts down a novel pathway for viral replication and also protects infected cells,” Ahmed G. Ibrahim, PhD, MPH, assistant professor in the Smidt Heart Institute at Cedars- Sinai and first author of the study, said in a statement.<\/p>\n

The new findings for potential treatment inhibits replication, but also protects or repairs tissue, an important step because COVID-19 can cause symptoms that affects patients long after being infected by the virus. Scientists say there are few treatments that exist for COVID-19, and the ones that do exist focus on preventing the virus from replicating.<\/p>\n

The therapy was developed by using skin cells call dermal fibroblasts.\u00a0Investigators at UCLA collaborated in the study and research.<\/p>\n

“Viruses don’t have their own machinery to get into cells, so they use proteins,” Ibrahim said. “We believe targeting ACE proteins is just one way SARS-CoV-2 infiltrates cells, hijacks their genetic information and replicates itself in the body.”<\/p>\n

Eduardo Marb\u00e1n, executive director of the Smidt Heart Institute and the Mark S. Siegel Family Foundation Distinguished Professor at Cedars-Sinai, said the COVID-19 biological therapy is “novel.”<\/p>\n

“This potential anti-COVID-19 biological therapy is novel in that it has two facets: It protects infected cells, which remdesivir does not do, and also inhibits viral replication,” Marb\u00e1n, senior author of the study, said.<\/p>\n

Investigators are planning future studies.<\/p>\n

–<\/p>\n","protected":false},"excerpt":{"rendered":"

Scientists from Cedars-Sinai report research findings have opened the possibility to a new therapy for COVID-19 patients, a discovery made in a biologic substance created by reengineered human skin cells. The substance stopped SARS-CoV-2, the virus that causes COVID-19, from reproducing and protected cells when tested in human lung cells, scientists reported. The research is […]<\/p>\n","protected":false},"author":70,"featured_media":98420,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_genesis_hide_title":false,"_genesis_hide_breadcrumbs":false,"_genesis_hide_singular_image":false,"_genesis_hide_footer_widgets":false,"_genesis_custom_body_class":"","_genesis_custom_post_class":"","_genesis_layout":"","footnotes":""},"categories":[15,1499],"tags":[],"_links":{"self":[{"href":"https:\/\/theavtimes.com\/wp-json\/wp\/v2\/posts\/107140"}],"collection":[{"href":"https:\/\/theavtimes.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/theavtimes.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/theavtimes.com\/wp-json\/wp\/v2\/users\/70"}],"replies":[{"embeddable":true,"href":"https:\/\/theavtimes.com\/wp-json\/wp\/v2\/comments?post=107140"}],"version-history":[{"count":2,"href":"https:\/\/theavtimes.com\/wp-json\/wp\/v2\/posts\/107140\/revisions"}],"predecessor-version":[{"id":107151,"href":"https:\/\/theavtimes.com\/wp-json\/wp\/v2\/posts\/107140\/revisions\/107151"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/theavtimes.com\/wp-json\/wp\/v2\/media\/98420"}],"wp:attachment":[{"href":"https:\/\/theavtimes.com\/wp-json\/wp\/v2\/media?parent=107140"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/theavtimes.com\/wp-json\/wp\/v2\/categories?post=107140"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/theavtimes.com\/wp-json\/wp\/v2\/tags?post=107140"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}